Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01697969 · ClinicalTrials.gov registry record · Phase 4
Confocal Analysis of Corneal Structures of Symptomatic Allergic Conjunctivitis Patients
A Phase 4 study, sponsored by Alcon Research.
- Completed
- Registry status
- Phase 4
- Development phase
- 17
- Enrollment target
NCT01697969 is a Phase 4 study that has completed, run by Alcon Research. The registered enrollment target is 17 participants.
The verdict
NCT01697969, a Phase 4 study, has completed, sponsored by Alcon Research.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 17 participants
- Enrollment target
Study Summary
The purpose of this study is to descriptively evaluate the corneal structures of allergic conjunctivitis patients.
Interventions
- DRUG Olopatadine hydrochloride ophthalmic solution, 0.2%
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2012-09 |
| Est. Completion | 2013-07 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01697969
The ClinicalTrials.gov registry entry for NCT01697969 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alcon Research, which has 275 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Olopatadine hydrochloride ophthalmic solution, 0.2% is the first listed.
NCT01697969 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01697969 about?
NCT01697969 is a clinical study titled "Confocal Analysis of Corneal Structures of Symptomatic Allergic Conjunctivitis Patients". The purpose of this study is to descriptively evaluate the corneal structures of allergic conjunctivitis patients.
What is the current status of trial NCT01697969?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 17 participants. The study started on 2012-09. Estimated completion is 2013-07.
What interventions are being tested in trial NCT01697969?
The interventions under investigation include: Olopatadine hydrochloride ophthalmic solution, 0.2% (DRUG).
Who is sponsoring clinical trial NCT01697969?
This trial is sponsored by Alcon Research, which has 275 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.